Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 4/20 | 0.51 |
| ▸ | CNR2 | P34972 | 3/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 2/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6893009 | 0.91 | BCAT2 (0.51) | MTNR1AMTNR1BBCAT2CNR1CNR2 | |
| SCHEMBL3141390 | 0.91 | BCAT2 (0.51) | MTNR1AMTNR1BBCAT2CNR1CNR2 | |
| SCHEMBL7487803 | 0.89 | NAAA (0.50) | MTNR1AMTNR1BBCAT2CNR1CNR2 | |
| SCHEMBL8419392 | 0.85 | MTNR1A (0.74) | MTNR1AMTNR1BBCAT2CNR1CNR2 | |
| SCHEMBL28694793 | 0.85 | MTNR1A (0.74) | MTNR1AMTNR1BBCAT2CNR1CNR2 | |
| SCHEMBL2726416 | 0.84 | MTNR1A (0.72) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL21199469 | 0.84 | CNR1 (0.51) | CNR1CNR2RIPK1CASRAOC3 | |
| SCHEMBL22689982 | 0.84 | CNR1 (0.51) | MTNR1AMTNR1BBCAT2CNR1CNR2 | |
| SCHEMBL28242821 | 0.84 | EPHX2 (0.75) | EPHX2NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL28242822 | 0.84 | EPHX2 (0.75) | EPHX2NPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9980928-B2 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2018-05-29 | — | — | US | disclosed |
| US-20170239197-A1 | HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2017-08-24 | — | — | US | disclosed |
| US-9624158-B2 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | PROUS INSTITUTE FOR BIOMEDICAL RESEARCH, S.A. (ES) | 2017-04-18 | — | — | US | disclosed |
| US-20170022180-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2017-01-26 | — | — | US | disclosed |
| EP-2945702-B1 | HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES | PROUS INST FOR BIOMEDICAL RES S A (ES) | 2017-01-11 | — | — | EP | disclosed |
| US-20160326142-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160287561-A1 | Inhibitors of AKT Activity | NOVARTIS AG (CH) | 2016-10-06 | — | — | US | disclosed |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-06-02 | — | — | US | disclosed |
| EP-2970099-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-8410158-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8273782-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| EP-1968568-A2 | INHIBITORS OF Akt ACTIVITY | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007076423-A2 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| CN-1235870-C | Novel use of phenyl hetero alkylamine derivatives | ASTRAZENECA AB (SE) | 2006-01-11 | — | — | CN | disclosed |
| CN-1411435-A | Novel use of phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-04-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | MTNR1A 4332/4885MTNR1B 4158/4885BCAT2 672/4885 |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | MTNR1A 22/4885MTNR1B 29/4885BCAT2 446/4885 |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, AKT3 | MTNR1A 4332/4885MTNR1B 4158/4885BCAT2 672/4885 |
| US-20160287561-A1 | Inhibitors of AKT Activity | AKT2, AKT1, AKT3 | MTNR1A 4332/4885MTNR1B 4158/4885BCAT2 672/4885 |
| US-20170239197-A1 | HYDROXY ALIPHATIC SUBSTITUTED PHENYL AMINOALKYL ETHER DERIVATIVES | SLC1A2, PNMT, DBH | MTNR1A 1435/4885MTNR1B 1033/4885BCAT2 54/4885 |
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | MTNR1A 4039/4885MTNR1B 3427/4885BCAT2 1733/4885 |
| US-20170022180-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | MTNR1A 22/4885MTNR1B 29/4885BCAT2 446/4885 |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | MTNR1A 4332/4885MTNR1B 4158/4885BCAT2 672/4885 |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | MTNR1A 22/4885MTNR1B 29/4885BCAT2 446/4885 |
| US-20160326142-A1 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | CYP3A5, GLP1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MTNR1A 2534/4885MTNR1B 2096/4885BCAT2 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.